Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H30N5O10P.C4H4O4 |
| Molecular Weight | 635.5149 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C
InChI
InChIKey=VCMJCVGFSROFHV-WZGZYPNHSA-N
InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20439609https://www.ncbi.nlm.nih.gov/pubmed/8452366Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9765248 | http://www.sciencedirect.com/science/article/pii/S2211383512001402
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609https://www.ncbi.nlm.nih.gov/pubmed/8452366
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9765248 | http://www.sciencedirect.com/science/article/pii/S2211383512001402
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA known as tenofovir) is an antiviral drug. Diphosphate of PMPA acts as a selective inhibitor of the HIV-1 reverse
transcriptase. Tenofovir disoproxil was approved for clinical use for the treatment of HIV infection (AIDS) and chronic HBV infection.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800020504https://www.ncbi.nlm.nih.gov/pubmed/8452366
Curator's Comment: reference retrieved from http://www.sciencedirect.com/science/article/pii/S2211383512001402
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765248 |
58.0 µM [Kd] | ||
Target ID: HIV-1, subtype A 92RW009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.3 nM [EC50] | ||
Target ID: HIV-2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.5 nM [EC50] | ||
Target ID: HBV replication Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646420 |
0.49 µM [EC50] | ||
Target ID: CHEMBL1892 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18060794 |
0.3 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | VIREAD Approved UseTenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections Launch Date2012 |
|||
| Primary | VIREAD Approved UseTenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections Launch Date2012 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
209.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
456.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
448.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
989.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
523.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.03 μg/mL |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
326 ng/mL |
245 mg 1 times / day multiple, oral dose: 245 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2079.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3006.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3408.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6373.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4476.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.4 μg × h/mL |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
3324 ng × h/mL |
245 mg 1 times / day multiple, oral dose: 245 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18.54 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
16.86 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
18.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23278367 |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18 h |
245 mg 1 times / day multiple, oral dose: 245 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
99.3% |
TENOFOVIR plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
||
99.3% |
245 mg 1 times / day multiple, oral dose: 245 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TENOFOVIR serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. | 2010-07 |
|
| Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. | 1998-10-16 |
|
| Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. | 1993-02 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02710604
For hepatitis B - 5-100mg tablet
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609
CMX-157 was active against all major subtypes of HIV-1 and HIV-2 in fresh human peripheral blood mononuclear cells (PBMCs) and against all HIV-1 strains evaluated in monocyte-derived macrophages, with 50% effective concentrations (EC(50)s) ranging between 0.20 and 7.2 nM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
VIREAD (AUTHORIZED: HEPTATITS B, CHRONIC)
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/14/1419
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
EVIPLERA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
FDA ORPHAN DRUG |
538416
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
FDA ORPHAN DRUG |
559316
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
TRUVADA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.1
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
VIREAD (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
202138-50-9
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
m10559
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | Merck Index | ||
|
63717
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
322248
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID5050426
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
TENOFOVIR DISOPROXIL FUMARATE
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | Description: White to almost-white, crystalline powder. Solubility: Slightly soluble in water, soluble in methanol, very slightly soluble in dichloromethane. Category: Antiretroviral (Nucleotide Reverse Transcriptase Inhibitor). Storage: Tenofovir disoproxil fumarate should be kept in a tightly closed container, protected from light and stored at a temperature between 2?8 ?C. Additional information: Tenofovir disoproxil fumarate may exhibit polymorphism. Definition: Tenofovir disoproxil fumarate contains not less than 98.5% and not more than 101.0% of tenofovir disoproxil fumarate(C19H30N5O10P,C4H4O4), calculated with reference to the anhydrous substance. Manufacture: The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 5 ppm for the mutagenic impurity 9-propenyladenine (impurity K), which may be a synthesis related substance, using a suitable method; ? a limit of not more than 1.0% for the tenofovir disoproxil (S)-enantiomer (impurity G) using a suitable chiral chromatographic method. | ||
|
OTT9J7900I
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
C47747
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
SUB12607MIG
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
100000092141
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
6398764
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
63718
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
KK-89
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
DBSALT000172
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
1643656
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
OTT9J7900I
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
CHEMBL1538
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY | |||
|
7165
Created by
admin on Mon Mar 31 17:58:14 GMT 2025 , Edited by admin on Mon Mar 31 17:58:14 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD